The volume of treatments available for idiopathic pulmonary fibrosis (IPF) is on the rise, with antifibrotic agents at the forefront of this surge. The Idiopathic Pulmonary Fibrosis Treatment Market is anticipated to grow from USD 3.89 billion in 2024 to an impressive USD 7.963 billion by 2035, representing a CAGR of 6.73%. As the understanding of IPF deepens, the development and adoption of...